REVIEW

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs

J Martel-Pelletier, D Lajeunesse, P Reboul, J-P Pelletier

Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada

Correspondence to:
Correspondence to:
Professor J Martel-Pelletier, Osteoarthritis Research Unit, CHUM, Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Pavillon deSève, Montréal (Québec) H2L 4M1, Canada;
jm{at}martelpelletier.ca

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

Keywords: cyclo-oxygenase; leucotrienes; 5-lipoxygenase; lipoxin

Abbreviations: AUC, area under the curve; COX, cyclo-oxygenase; FLAP, 5-lipoxygenase activating-protein; GI, gastrointestinal; IL, interleukin; 5-LOX, 5-lipoxygenase; LT, leucotriene; LX, lipoxin; NO, nitric oxide; NSAIDs, non-steroidal anti-inflammatory drugs; PG, prostaglandin; PMN, polymorphonuclear cells; TXA₂; thromboxane A₂

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Tavolari, S., Bonafe, M., Marini, M., Ferreri, C., Bartolini, G., Brighenti, E., Manara, S., Tomasi, V., Laufer, S., Guarnieri, T. (2008). Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29: 371-380 [Abstract] [Full Text]  
• Horrillo, R., Planaguma, A., Gonzalez-Periz, A., Ferre, N., Titos, E., Miquel, R., Lopez-Parra, M., Masferrer, J. L., Arroyo, V., Claria, J. (2007). Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. J. Pharmacol. Exp. Ther. 323: 778-786 [Abstract] [Full Text]  
• Vidal, C., Gomez-Hernandez, A., Sanchez-Galan, E., Gonzalez, A., Ortega, L., Gomez-Gerique, J. A., Tunon, J., Egido, J. (2007). Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis. J. Pharmacol. Exp. Ther. 320: 108-116 [Abstract] [Full Text]